Abbott Laboratories

Good morning, and thanks for joining us. Also on today's call will be Tom Freyman, Executive Vice President, Finance and Chief Financial Officer; and Larry Peepo, Divisional Vice President of Investor Relations.

Tom will review the details of our financial results for the quarter, as well as our outlook for the year. Larry and I will then discuss the highlights of our major businesses.

Following our comments, we'll take any questions you may have, as always. Some statements made today may be forward-looking, including the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the 2 companies after the separation.

Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect Abbott's operations are discussed in Item 1a Risk Factors to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2011, and are incorporated by reference.

We undertake no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments. In today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance.

These non-GAAP financial measures are reconciled with the comparable GAAP financial measure in our earnings news release and regulatory filings from today, which will be available on our website at abbott.com. And with that, I'll turn the call over to Tom.

Tom?

Thanks, John. As you can see from our earnings news release this morning, we had a very strong first quarter, delivering double-digit ongoing earnings per share growth and beating our original forecast.

We're very pleased with our start to the year and our outlook for the remainder of 2012. As a result, today, we are raising our ongoing EPS guidance range for the full year 2012 by $0.05 on both the bottom and the top of the range, reflecting another year of top-tier performance.

For the first quarter, we reported ongoing diluted earnings per share of $1.03, an increase of 13.2% over the prior year. Sales increased 5.9% on an operational basis, that is excluding an unfavorable 1.3% impact from exchange rates, which was driven by strong performance across a number of our products and businesses.

Reported sales increased 4.6%. In emerging markets, broadly defined, sales increased more than 10%, excluding the negative impact of foreign exchange, with double-digit growth in key emerging markets across the businesses.

We also saw meaningful improvement in the adjusted gross margin ratio, up 260 basis points from the prior year to more than 61% as a result of the many margin-improvement initiatives we're implementing company-wide. In the quarter, we drove better margin performance across our major businesses, including Proprietary Pharmaceuticals, Vascular, Nutritionals and Diagnostics.

We delivered more than 13% ongoing EPS growth and a 150 basis point improvement in our adjusted operating margin while continuing to invest in the businesses. Ongoing R&D investment was 10% of sales, reflecting continued progress across our new product programs.

We also accelerated SG&A investment behind many of our key products and businesses to drive future growth. In the non-operating section of the P&L in the quarter, the net foreign exchange (gain) loss line was unfavorable $58 million compared to 2011.

Other income in the quarter included a $60 million favorable resolution on a contractual agreement. These 2 items, therefore, offset the quarter with neutral effect.

Turning to our outlook for the full year 2012, we're raising both our ongoing earnings per share guidance range $0.05 on both ends of the range to $5 to $5.10. With our planned separation on track for completion by the end of the year, the guidance we've provided continues to reflect a full year outlook for the company in total.

Regarding sales growth for 2012, we continue to forecast operational growth in the mid-single digits. Based on current exchange rates, we continue to expect a negative impact of exchange on sales of approximately 2.5% for the full year.

As a result, reported sales growth is expected to be in the low single digits, in line with the forecast we've provided in January. Also for 2012, we're forecasting continued improvement in our adjusted gross margin ratio, which we continue to expect to approach 62% for the full year.

This reflects efficiency initiatives and favorable mix, partially offset by the expected decline in U.S. lipid sales and promised royalties.

We're forecasting continuing investments to drive growth in 2012 and beyond, with full year R&D of 9.5% to 10% of sales and ongoing SG&A somewhat under 28% of sales. Overall, we continue to expect to expand our operating margin by around 100 basis points in 2012.

We're forecasting ongoing net interest expense of approximately $425 million, and we continue to expect an ongoing tax rate of 14.5% to 15% for the full year 2012. Turning to the outlook for the second quarter.

We're forecasting ongoing earnings per share of $1.20 to $1.22. We forecast specified items of $0.07 in the second quarter, primarily reflecting costs of previous restructuring and integration actions.

This forecast excludes future one-time costs related to the separation. Our operational sales growth in the second quarter, that is growth before exchange, is expected to be in the mid-single digits.

At current exchange rates, we expect a roughly 3.5% negative impact from exchange in the second quarter, resulted in -- resulting in reported sales growth in the low-single digits. We're forecasting an adjusted gross margin ratio of approximately 62% in the second quarter, an increase from the second quarter of 2011.

As mentioned, we remain on track with our plans to separate Abbott into 2 leading health care companies, one in diversified medical products and the other in research-based pharmaceuticals. We believe this separation will provide 2 unique and compelling investment opportunities for shareholders.

Our transition organization has been fully engaged in this separation since our announcement last October. This is the same organization that executed the separation of our hospital products business and successfully integrated our key acquisitions.

We're currently working through the many details of separating the 2 organizations. There's a significant amount of work to do, but the process is going well and is proceeding according to plan.

Last month, we announced that the new research-based pharmaceutical company will be called AbbVie. The AbbVie name connects the new company to Abbott and its heritage of pioneering science, and the "Vie," which suggest the Latin root for life, calls attention to the vital work the company does.

During the second quarter, we expect to file the initial Form 10 with the SEC for AbbVie. The Form 10 will provide historical results for AbbVie on a GAAP basis for the past 3 years and for the first quarter of 2012.

These historical results will include an allocation of certain costs previously held at the corporate level to the business. Amendments are typically made to the Form 10 disclosures after the initial filing as more information becomes available for disclosure, including future quarterly results.

We'd expect amendments to our filing as well until it's declared effective, which is expected to occur later in the year. The historical balance sheet is not expected to include an allocation of debt to AbbVie such as debt -- as such debt was incurred for the total Abbott operations and was not associated with specific AbbVie entities.

The final or effective Form 10 will, however, include pro forma adjustments to reflect the impact of debt levels, cash balances and interest expense for AbbVie as an independent company. The Form 10 is one element in our communications plans for AbbVie and for Abbott post the separation.

We will also have comprehensive industrial relations efforts throughout the year to provide investors with information on the 2 companies as we progress towards the separation. So in summary, we're off to a great start in 2012, beating expectations for the first quarter and raising our outlook for the full year.

This outlook again reflects strong and top-tier performance as we execute the steps necessary to separate Abbott into 2 leading health care companies by the end of the year. With that, let's turn to the business operating highlights.

John?

Thanks, Tom. I'll start with the diversified medical products businesses, and then Larry will discuss the Proprietary Pharmaceutical business.

Sales for our diversified medical products businesses increased mid-single digits in the first quarter, excluding the negative impact of foreign exchange. We also continued to expand operating margins on the quarter across our diversified medical products businesses including Nutrition, Diagnostics, Vascular and Diabetes Care.

Let's start with Nutrition, where global sales in the quarter increased more than 10%, driven by strong growth in both the U.S., as well as international. In the U.S., sales increased 11% as we continue to maintain our strong market positions in both the Adult and Pediatric Nutritional segments.

U.S. Pediatric Nutrition sales increased more than 15%.

We continued to gain share and maintain our strong leadership position in the U.S. infant formula market with Similac.

We expect continued strong growth of this brand throughout the year as we launch new products to support Similac in the prenatal segment of the market. Our toddler brand, PediaSure, continues to grow at a double-digit pace.

U.S. Adult Nutritional sales increased more than 7%, driven by double-digit growth of both Ensure and Glucerna.

We expect Ensure and Glucerna collectively to generate roughly $2 billion in full year sales this year, globally. Earlier this week, we initiated construction at a new liquid manufacturing facility in Ohio that will primarily support the growth of our U.S.

Adult business. Abbott is the worldwide leader in adult nutrition.

And as the baby boomer demographic ages, we expect continuing market expansion of the Adult Nutritional segment. Outside of the U.S., sales increased approximately 10% on an operational basis in Nutritionals, including the negative impact of foreign exchange, reported sales increased more than 9%.

This growth was driven by 13% growth in Pediatric Nutritionals, with double-digit growth in Infant Nutritionals, as well as PediaSure. In the first quarter, we initiated more than 10 new product or geographic launches, each of which is helping to drive market share gains.

Emerging market sales comprised more than 40% of our total nutritional sales, and they increased double-digits this quarter. In addition to driving sales growth, the key priority for our Nutrition business is the expansion of operating margins.

We've implemented an improvement plan to expand our Nutrition margin from the low teens that we saw last year in 2011 to our target of more than 20% by 2015. We have numerous efforts across the business, with 4 main drivers of margin improvement.

Those are: product costs, where we're reducing packaging cost, ingredient costs and material costs; manufacturing, where we're building plants closer to our customers, particularly in fast-growing emerging markets; distribution, where we're going direct to customers in key geographies; and customer mix, where we're improving both our product and geographic mix to focus on more profitable segments. We're implementing the majority of these improvement initiatives here in 2012, which are expected to drive significant Nutritionals operating margin expansion in 2013 and beyond.

As we look ahead to the second quarter in our global Nutritionals business, we expect high single-digit growth on an operational basis, and mid to high single-digit growth on a reported basis. In the U.S., this includes high-single growth; and internationally, this includes high single-digit growth on an operational basis and mid single-digit growth on a reported basis.

Let's move on to our Established Pharmaceuticals business, or EPD, which includes international sales of our branded generics portfolio. Sales in the quarter increased 2% on an operational basis.

Including a 3.5% negative impact of foreign exchange, reported sales declined low-single digits. Emerging markets now represent nearly 60% of total EPD sales, where many of the pharmaceutical markets are growing at a strong double-digit pace.

We're growing faster in these markets as we continue to expand our presence and launch new brands, packaging enhancements and new formulations. In the first quarter, EPD's operational sales in key emerging markets such as India, Brazil, Russia and China increased collectively 17%.

Our large and growing portfolio of more than 500 Established Pharmaceuticals consists of trusted, well-known brands that have broad use throughout the world. Over the next several years, we expect to bring the benefits of these medicines to much broader patient populations through registrations across multiple geographies, as well as launches of improved formulations to enhance efficacy and improved convenience.

So looking ahead to the second quarter in EPD, we expect low single-digit sales growth on an operational basis and a low single-digit decline on a reported basis, which includes, for this division, an expected negative impact of foreign exchange of more than 6% in the second quarter. In our global Diabetes Care business, worldwide reported sales declined 2.4%.

U.S. sales increased more than 7% as we continue to execute on our strategy to drive share gains among the insulin-using patient population.

We also recently launched InsuLinx in the U.S., which is our new blood glucose meter specifically for this segment. InsuLinx has a touch screen interface and several personalization features designed to improve the diabetes management experience for patients.

International sales in our Diabetes Care business declined 7% on an operational basis. Including the negative impact of exchange, reported sales declined 8.7%, due in part to certain reimbursement changes in Europe, as well as overall market softness.

The negative impact in Europe was partially offset by stronger growth in emerging markets. So looking ahead to the second quarter in Diabetes Care, we expect low to mid single-digit sales growth on an operational basis and low single-digit reported sales growth.

In our Core Laboratory Diagnostics, which includes immunoassay, hematology and blood screening, global sales in the quarter increased more than 6% on an operational basis. Reported sales increased 5%.

In the U.S., sales increased nearly 13%. This strong growth was driven by continued uptake of our PRISM blood screening system and good momentum that began in the latter part of last year with several key account wins and continued strong commercial execution.

Outside of the U.S., operational sales increased 5%, and reported sales increased 3%. We delivered strong growth in emerging markets, with sales in China, Brazil and Russia collectively increasing 25%.

In each of these markets, we continue to expand our presence with numerous new account wins internationally, including the largest private laboratory in Latin America. In Point of Care Diagnostics, worldwide operational sales this quarter increased more than 19%.

And in Molecular Diagnostics, worldwide operational sales increased nearly 8%. Reported Molecular sales increased 6%.

Looking ahead to the second quarter in our global Diagnostics business, we expect mid to high single-digit growth on an operational basis and mid single-digit reported sales growth. So moving on to medical devices and our Vision Care business, where global sales this quarter increased low single digits.

This was primarily driven by mid single-digit growth in cataract, our largest, most profitable and fastest-growing segment within Vision Care. We also saw a continued, strong double-digit growth in emerging markets such as India and China.

Looking ahead to the second quarter in our Vision Care business, we expect low single-digit sales growth on an operational and reported basis. In our Vascular business, excluding certain royalty and supply arrangement revenues, worldwide Vascular sales increased nearly 4%, and U.S.

Vascular sales increased 8%. As expected, reported sales decreased 5% this quarter as a result of a more than 50% decline in royalty and supply arrangement revenues, including PROMUS.

As a reminder, the third-party distributor for PROMUS is transitioning away from this product as we approach the end of our distribution agreement this year. Our Vascular business also delivered strong growth in key emerging markets such as China, India and Brazil, which all increased at strong double-digit growth rates.

Sales of our XIENCE drug-eluting stent franchise this quarter were a record $404 million, representing global growth of nearly 7%. Abbott holds the clear global leadership position as the world's #1 drug-eluting stent company.

U.S. XIENCE sales increased more than 19% this quarter, driven by the recent U.S.

launches of XIENCE nano and XIENCE PRIME, as well as share gains from key account wins in the U.S. as we further penetrate competitor accounts and broaden our overall footprint.

More than 60% of our drug-eluting stents sales occur outside the United States. In Japan, which is our second largest geographic segment, we hold market share of more than 40%.

We recently received approval for XIENCE PRIME in Japan and now have the exclusive position in the long-length Everolimus Eluting stent segment. Also contributing to Vascular sales growth this quarter was endovascular sales, which increased nearly 5%.

In the past year, we've launched 7 new endovascular products, including, most recently, U.S. approval for Absolute Pro, our new self-expanding stent for peripheral artery disease.

In our Vascular pipeline, we recently presented 2-year data on our ABSORB Bioresorbable Vascular Scaffold, or BVS, which demonstrated impressive efficacy and safety results for the treatment of coronary artery disease. We also have 2 clinical trials underway, studying BVS for peripheral disease.

We continue to expect a full commercial launch of ABSORB in Europe by year end, and plan to initiate our U.S. clinical trial later this year.

MitraClip, which is our product for the treatment of mitral regurgitation, continues to see strong demand outside of the United States, with sales of $25 million this quarter. So as we look ahead to the second quarter on our global Vascular business, excluding the negative impact of foreign exchange as well as certain royalty and supply arrangement revenues, we expect sales of our underlying business to grow in the high single digits.

Including the expected decline of royalty and supply arrangement revenues, as well as the negative impact of foreign exchange, we expect reported sales to decline low single digits in the second quarter. As a reminder, the PROMUS transition will be completed by the end of the year, positioning our Vascular business in 2013 for stronger reported sales growth.

Finally, as Tom mentioned, the adjusted operating margin in the first quarter for the total company increased approximately 150 basis points over 2011. Nutrition, Diagnostics, Vascular and Diabetes Care contributed to this expansion, with most of the diversified medical products businesses each delivering at least 100 basis points or more margin expansion in their businesses.

In Nutrition, as I mentioned, we expect to expand the operating margin from the low teens today to more than 20%. This quarter, we saw a good progress towards that goal.

In Diagnostics, in addition to strong sales growth, we continue to expand our operating margins following a record year of profitability in 2011. As a reminder, this business has had a high single-digit operating margin just a few years ago.

This quarter, we delivered an operating margin in the high teens. We're applying many of our key learnings from the work we've done to improve profitability in our Diagnostic business to our efforts to improve profitability in our Diabetes Care business, where we continue to see good improvement on the bottom line.

And in Vascular, despite the decline in PROMUS revenues, which were expected, we delivered operating margin in the high 20s in the quarter. We expect continued steady margin expansion for our diversified medical products businesses over the course of the year and going into 2013 and beyond.

So with that, I'll turn the call over to Larry to cover our Proprietary Pharmaceutical business. Larry?

Thanks, John. Worldwide Proprietary Pharmaceutical sales increased more than 8% before the negative impact of exchange.

On a reported basis, sales increased 7%, including growth of 6.6% in the U.S. and nearly 8% internationally.

In immunology, global sales of HUMIRA increased more than 19% before the negative impact of exchange. Performance was driven by international sales growth of 17.4% before exchange and U.S.

sales growth of 22.7%, consistent with the underlying trends we saw throughout the quarter. HUMIRA continues to hold the #1 global share position.

We continue to see strong market growth both in the U.S. and internationally, with HUMIRA demand outpacing the market.

We're continuing our development efforts for HUMIRA, including the study of new indications. We recently received approval from the European Commission for the treatment of ulcerative colitis, making HUMIRA the first and only self-injectable biologic therapy for this disease.

The approval also marks the seventh major indication for HUMIRA in the European Union. We also have a number of other indications currently in late-stage development, many of which are unique to HUMIRA.

HUMIRA's utility across a growing number of diseases is one of the many attributes that set it apart from other agents. HUMIRA is off to a strong start this year, well on track to achieve our sales growth outlook for the product in 2012.

Moving on to AndroGel where U.S. sales were approximately $230 million, up more than 23%.

AndroGel holds the #1 market share position in the testosterone replacement market, where growth is being driven by increasing diagnosis and treatment. AndroGel 1.62, our new low-volume formulation, has quickly become the second most-prescribed therapy in the market, second only to our older formulation AndroGel 1%.

U.S. sales of CREON were nearly $70 million.

CREON maintains market leadership in the pancreatic enzyme market, where we continue to capture the vast majority of new prescription starts. U.S.

sales of Lupron were $140 million. Our 6-month formulation, approved last year, continues to perform well, driving share gains and expanding our category leadership.

U.S. sales of Synthroid were approximately $130 million in the quarter.

Synthroid maintains strong brand loyalty and retains more than 20% market share despite the entry of generics into the market many years ago. Moving on to our more mature lipid franchise, where U.S.

TriCor/TRILIPIX sales were $254 million and sales of Niaspan were $190 million. Our lipid franchise has been impacted by softness in the overall branded cholesterol market, as well as continued impact from last year's ACCORD and AIM-HIGH study results as we've previously discussed.

So as we look ahead to the second quarter in our global Proprietary Pharmaceuticals business, we expect mid- to high-single digit operational sales growth and a forecast for approximately 3% negative impact from foreign exchange. Moving on to our Proprietary Pharmaceuticals pipeline where we continue to make good progress.

We currently have 30 compounds in human trials, including numerous medicines in development with breakthrough potential. Let's start with immunology, where we have a number of next-generation programs underway, all with an objective to raise the bar with differentiated efficacy and safety.

This high bar is important as we believe the success of new compounds will be based on their ability to offer incremental efficacy and safety benefits beyond what's currently available to physicians and patients today. Our DVD-Ig platform holds promise in the treatment of RA, as well as other conditions.

This proprietary technology unites 2 antibodies into a single molecule. Last year, we initiated a Phase I study in RA for ABT-122, which combines the established mechanisms, anti-TNF and IL-17, with the goal of elevating efficacy and improving the overall clinical profile.

Our anti-CD4 biologic, BT-061, in development in partnership with Biotest, is currently in Phase II clinical trials for RA and psoriasis. The way we've structured the collaboration allows us to evaluate Phase 2b data prior to co-funding the Phase III program.

And the product will need to demonstrate a clinically meaningful efficacy benefit, greater than currently available therapies, to clear the hurdle for advancement. Our recently announced agreement with Galapagos to develop and commercialize a next-generation oral JAK1 inhibitor is structured similarly.

We believe this molecule, which preferentially targets the JAK1 pathway, differentiates it from other JAKs in development and may lead to a better overall profile. The Galapagos compound is currently in Phase IIa development with the potential to start Phase IIb next year.

We are also evaluating a number of other oral candidates including an internal JAK1, a SYK inhibitor, as well as next-generation anti-inflammatory modulators, or AIMs through our collaboration with Reata. Moving on to chronic kidney disease, which is also on the rise, driven by higher rates of diabetes, obesity and an aging population.

Bardoxolone is a promising treatment in Phase III development for CKD with our partner Reata. Bardoxolone is a nerve 2 activator, a novel mechanism that improves the kidney's ability to filter and remove waste from the body.

Results from the Phase IIb study of Bardoxolone were unprecedented and showed a significant and sustained improvement in kidney function. No other treatment to date has demonstrated the ability to reverse the progression of this disease.

The Phase III study called BEACON is an outcomes-based study designed to assess Bardoxolone's ability to forestall or prevent chronic dialysis, kidney transplant or cardiovascular death in Stage 4 patients, a group that is just pre-dialysis. Enrollment has been very brisk, which reflects the significant need for new therapies in this disease.

We expect results from this 2,000-patient global trial in 2013. Also in development for the treatment of kidney disease is atrasentan.

Results from a Phase II dose-ranging trial showed atrasentan reduce protein in the urine, a symptom that is often predictive of renal function. We would expect atrasentan to be complementary to Bardoxolone within our portfolio.

A Phase IIb study is currently underway, with results expected later this year. Moving on to neuroscience where we're developing compounds to address conditions such as Alzheimer's, Parkinson's, schizophrenia, pain and MS.

Daclizumab is a next-generation biologic in development for MS. Last year, Abbott and our partner company announced promising results from the first of 2 registrational studies.

The first -- the Phase III study called DECIDE is ongoing. In this study, we hope to confirm the findings observed in the Phase II trial.

If successful, we believe a significant reduction in disability and annual relapse rate against an active comparator will be data that is unique to this promising and highly active treatment. Results from the Phase III study are expected in 2014, with potential commercialization in 2015.

We're also developing an intestinal gel for the treatment of advanced Parkinson's disease. The gel, currently in advanced clinical development in the U.S.

and marketed as Duodopa in Europe, consists of 2 compounds with proven efficacy in this disease, levodopa and carbidopa. Through a unique delivery system, the intestinal gel is infused directly into the small intestine via a portable pump.

Yesterday, we announced the results from a Phase III trial, showing patients treated for 12 weeks reported significant improvements in disease symptoms versus the oral forms of the products. The results from the study will be presented at the American Academy of Neurology meeting later this month.

We expect our U.S. registration submission to occur this year.

Endometriosis and fibroids are both associated with a number of symptoms, including pain and infertility. Our partnered compound, elagolix, has a unique profile that provides symptom reduction while avoiding the adverse effects that can sometimes be associated with current treatments.

The Phase II clinical program for fibroids is currently underway, and the Phase III study in endometriosis is expected to begin this quarter. Moving on to oncology where we're focused on developing targeted treatments that inhibit tumor growth and improve response to common cancer therapies.

Elotuzumab is being developed with a partner company for the treatment of multiple myeloma, the second most common blood cancer. Phase II data suggests the potential for improved efficacy versus current treatments.

The Phase III study for Elotuzumab is currently underway. We also have active PARP and Bcl-2 inhibitor programs, as well as a number of other early-stage oncology compounds in development.

And finally, turning to our rapidly advancing HCV program where we have a broad portfolio with compounds spanning 3 mechanisms of action, including protease, non-nucleoside polymerase and NS5A inhibitors. Recent data suggest the combination regimen will likely prove to be the most effective approach, and we're well positioned in that regard, given our portfolio.

Earlier this month, abstracts for the upcoming EASL meeting were published online, including results from 2 of Abbott's Phase II interferon-free HCV studies, Pilot and Co-Pilot. In the Co-Pilot study, 2 different doses of our protease inhibitor, ABT-450; plus our non-nucleoside polymerase inhibitor, ABT-333 and ribavirin, were administered for 12 weeks.

The results showed sustained virologic response at 12 weeks post-treatment in 93% and 95% of treatment-naïve genotype 1 patients. In these patients, response was independent of HCV subtype host IL28B genotype or dose level of ABT-450.

The Pilot study evaluated treatment with ABT-450 plus another of our non-nucleoside polymerase inhibitors, ABT-072, and ribavirin for 12 weeks. The results showed sustained virologic response at 12 weeks post-treatment in 91% of genotype 1 treatment-naïve patients.

Both regimens were well tolerated, and the most reported adverse events were mild in severity. Full results with longer term follow-up data from these studies as well as a number of other abstracts will be presented at the EASL meeting this week in Barcelona, Spain.

We're building on the Pilot and Co-Pilot results with data from our larger global Phase II clinical trials. These studies include various combinations of all 3 compounds in our portfolio, both with and without ribavirin, as well as evaluation across various HCV genotypes.

Additional data from these studies, which are planned for presentation later this year, will shed further light on our promising program. We have a high level of confidence that our HCV compounds in development will dramatically change the treatment landscape.

We expect to start Phase III studies in 2013 with commercialization in 2015, putting us in a very competitive position from a timing perspective. So in summary, this quarter, Abbott delivered strong double-digit performance with ongoing EPS growth of more than 13%, and we raised our ongoing earnings per share guidance for the year.

We remain focused on the process of separating Abbott into 2 leading healthcare companies, which is on track to be completed by the end of the year. And with that, Tom, John and I will be glad to take your questions.

Operator?

As we think about operating margins, Tom, I mean, clearly, in particular on the Nutritional side, John laid out very thoroughly and clearly some of the drivers there. Can you talk a little bit more, just over the next -- looking ahead over the next couple of years and as the company separates, what are the bigger -- biggest margin drivers beyond this Nutritionals program?

Is it diabetes? What's next?

And is this going to be -- are these similar programs that you laid out for Nutritional? Or is it more about cost?

Just, again, any perspective would be welcome. Where do we go from here?

Well, I think what John said in his remarks is a good representation of the way we're approaching it. And I think our experience in diagnostics really helped a lot in this regard.

And we talked about this in the past. What that team did is they didn't limit their analysis of their business to just the cost area.

They really looked comprehensively at their P&Ls, all the way from the top to the bottom line. They did a lot of thinking through mix, product mix, customer mix, profitability by customer segment.

And they did some very good analytics and addressed some of the challenges there that really weren't evident as we looked at these businesses differently, prior to their -- to the work they did in that area. And we've really taken that approach and that template and brought it over to the other businesses and very comprehensively looked at each.

So -- as John described in his Nutritional discussion there, it's a pretty broad range of things beyond just the cost area. And our other businesses have done similar exercises.

In terms of what's going to drive operating margin improvement for the diversified company, certainly, the biggest opportunity over the next 2, 3 years is nutrition. I think that's where we see the highest ramp.

We were -- in the 13 range, I think an operating margin couple of years ago, and we see a very good path to 20 here the next 2, 3 years, and we have a very thorough plan to get there. So that clearly is the biggest mover.

But every single business is continuing to execute on their programs, again similar to what Diagnostics did. And we see steady improvement in each business, including Diagnostics.

While we've gotten that business up into the upper teens, we clearly see that getting well into the 20s in the next couple of years as well, as they continue to execute. So it's a way of doing business.

It's a continual process. And I think, across the businesses, it's going to contribute to a good margin expansion element of the diversified company as we move forward.

And follow-up with 2 product or division-related questions. Core Lab U.S., up 13%, an excellent performance.

Maybe highlight some other pipeline products and how sustainable. And last, on ABSORB, given the EU launch later this year, maybe you could update us in terms of just some basic expectations about the penetration the product is likely to get in the first year or so post-launch?

Yes, let me take the first part. So ABSORB has been doing well in a limited clinical setting, as we've described before.

And then we expect full commercialization launch later this year. The reaction has been very good from clinicians around the world.

And as you know, the data results that we've showed so far are similar to what we have seen with XIENCE and XIENCE PRIME in terms of the safety profile and the efficacy. So very encouraged there.

And as I mentioned, later this year, plans to start the U.S. trial remain on track there.

So it's a good story there. In Core Lab, it's been -- it's interesting because it's a business, frankly, that we haven't talked a lot about, the different products and tests like we used to.

But there have been a number of new products that have been launched, new assays. PRISM obviously has been important as that expands.

We had good growth there with both of those systems, particularly in some emerging markets around the world where -- markets like China, we've grown in excess of 35%, grown twice the market. Brazil, we've had very good traction with our Vitamin D and Chagas test.

Russia is growing, excess of 30%. It's off a smaller base.

But we're really investing in some of those emerging markets, and leveraging our overall global leadership position is definitely making a big difference. And then as I mentioned in my remarks, we did win the largest private laboratory in Latin America in the first quarter this year.

So those are the good things. The European market has been a little challenging, I think, for everybody.

Other competitors have talked about that, but that's one of the things that you have to deal with and we plan for. We also have had some specific tests in the pipeline last year, for example, the Vitamin D test that I mentioned; launched a number of new assays this year, include diabetes and cardiac markers.

And then we have other things that we've done in that business, as you know, with our acquisition of STARLIMS. That was the first -- our first entrée into informatics.

And we've launched what we call OneLab, which is an offshoot of the STARLIMS system. That's gaining some good traction and giving our customers some options that they didn't have before.

So first one -- let me ask on Hep C. So what are we going to see additionally at EASL that we didn't see in the abstracts?

Most of our abstract, Mike, this is Larry, contain the information that we have at EASL. So when they posted earlier this month, that pretty much encompassed all of our data.

And again, the key data there for us would be the Co-Pilot data, which showed very strong SVR12 rates of 93% and 95%. And then Pilot also was very strong.

SVR rates, SVR24 actually, at 91%. But most of the abstracts that have been released back in early April will be comprehensive of what we have at EASL this weekend.

One of the questions that people have had has been bounced about on the Street post the release of the abstracts, is the difference in the response rates between the non-CC naïve patients and those that are non-CC treatment failure patients, interferon failure patients. Do you have any thoughts as to why there's such a difference in response rates between those 2 groups?

Obviously the N is small, but there's a pretty strong difference there.

Well, people who are non-responders are certainly the most difficult to treat, right? And this data that we have right now is kind of our first foray into that group, and it does only include 2 of our agents, the protease inhibitor, as well as the polymerase.

And so, as you know, we've got additional studies underway, CC, as I mentioned, later this year, that are inclusive of the NS5A, which we believe to be a much more potent group. But that 47% SVR rate within that non-responder group is actually better than just about anything else that's been put forth to date, including some pretty low-level response rates from the new class that we've seen here over the last 6 weeks.

So I would say that 47% looks very good relative to anything else that we've seen. And I think we'll see more again later this year when we put together a more potent agent NS5A in combination with this tough-to-treat patient population.

Yes. And then, of course, Mike, the other data that we showed in the most prevalent form of the virus in developed markets, the GT1 treatment-naïve patients, that's where we saw the cure rates in excess of 90%.

So those were unprecedented types of results. It's obviously, as Larry said, early data, and we expect to have more data later in the year on a broader patient population.

But clearly, I think that put us in a leadership position in HCV.

Good. Let me ask one question on EPD.

The performance this quarter was a bit light of our thinking. I think it was up 1.8% constant currency.

At the Analyst Meeting, you guys had talked about EPD growing mid- to high-single digits going forward, and I know emerging markets are close to 60% of the revenues. So help us out there, what is going on in EPD?

It's important because it's 1/3 of the profits for new Abbott, so it's going to be a key driver. So why is growth in the low-single digits right now?

Why isn't it in that mid to high single-digit range you guys talked about?

Well, obviously, that mid to high was a bit of a longer-term target for this group. And the results in the first quarter were very consistent with the guidance we provided in January.

And what's happening -- this organization has been in place for a little more than the year. There are a number of their geographic expansion initiatives and products expansion initiatives, which are just in the early stages.

Programs such as the Zydus collaboration, which will bring new molecules to the market, and some of the payback on some of the commercial investments that have been made over the last -- over the first year or so are still a bit further out. So I think we're on track in the first quarter.

We do expect the growth rates to improve later in the year. There's been -- as you know, there is a base part of this business that is the developed world that is growing a bit more slowly.

And in the first quarter, we were working through a little bit of a headwind in some of the European countries there as we progressed through the year. But I think the comps will get better, particularly in the third and fourth quarter.

And as we exit the year, our forecast show that we'll be much closer to that range we talked about at the Analyst Meeting as we progress into 2013. So we expect better growth.

I think you'll see it. And we'll just have to keep monitoring it as we go forward.

Just a few questions, Tom. TriCor, what are your expectations for revenues going forward?

Just given the settlement that you've reached with Teva, and Teva's commentary that the FDA has issues with their formulation and won't be launching this year, do you anticipate that there will be other generics on the market? And does your settlement agreement allow for other generics to reach the market?

And then I have a follow-up question on HUMIRA growth, which has been quite remarkable in terms of the re-acceleration we've seen, with HUMIRA growth in the U.S., along with the entire anti-TNF class. And I'm just wondering what you think is going on.

And as you know, there will be a JAK inhibitor potentially reaching the market in the second half of this year and if your guidance for the full year incorporates a competitive dynamic, and if you could just share with us what you're thinking is.

Yes, so this is Tom. On TriCor, I mean, I've heard some of the comments you mentioned from Teva, but we can't make assumptions on what they're going to do or not going to do.

And clearly, they have a right to enter the market in the second half. And so we continue to model that.

I think even if there was somewhat of a delay there, over the -- even the near term or the medium term, that's not real meaningful for us because clearly, as we move into 2013 and '14, these lipid products are in their last phases, and we don't have expectations for sales for those products. So that issue may be a little more meaningful for the other company than it is for us, and we'll see how it plays out in the second half.

John, you want to take -- or Larry, you want to take the HUMIRA?

Sure. This is Larry.

The market growth has been very strong for biologics overall, and I think you'll see that our growth from a prescription trend basis is growing even faster than the market. I think, from an overall market, maybe we're seeing a little bit more contribution from the dermatology side, which, as you know, has very low levels of penetration currently.

I think that's lifting the overall biologics market. I think unique to HUMIRA has just been some very strong commercial execution across all the categories.

We continue to see very good share momentum, particularly in dermatology relative to Enbrel, as well as in the gastro space relative to the Cimzias of the world. We continue to see really nice market share gains there.

And room has held in there quite nicely for us as well, despite an increased level of competition from smaller players who have garnered, I would say, pretty low levels of share overall. Now you asked about our contemplation of a potential launch of Pfizer's tofacitinib product.

We pretty much as -- almost like in the TriCor situation, we have to assume that they will be successful with their ultimate approval on a PDUFA date, which I believe is in August. And so we've factored that into our outlook for the year.

And certainly, we feel very good about our position, the strength of HUMIRA relative to that product's launch. But to your specific question, yes, we have factored that into our outlook for this year.

And just, Tom, very quickly on your tax rate guidance for the year of 14.5% to 15%. Does that contemplate an R&D tax credit?

Is that already in that number?

No, we do not assume that at this point in time.

Tom, just wanted to come back to EPD for a second. So it does appear that the key emerging markets with NS7 are performing actually quite well.

So I wonder, is the performance today, which I know you hope to get better, is that more a function of the BRICs not growing as fast as you want or expected? Or is it a situation with the non-BRIC markets that may be more developed in nature are being pressured for economic reasons kind of at this current time?

Yes, it's -- well, it's the non-BRIC. But all -- we, frankly -- as we look at this business not really on the long term, the medium term, we have factored into that mid to upper expectation on sales growth, the fact that this base business will not grow as fast.

But as the emerging markets grow as fast as we expect, and as it becomes a higher percentage of the business, I think it's going to support growth in the range that we have targeted. I will say, as a part of the latter part of 2011 and in the first quarter of 2012, there still is some residual austerity effect coming through in the developed world element of this business.

And that's a little bit of what you're seeing in the first quarter, a bit of headwind. But in the BRIC areas, very strong double-digit growth, and we're really pleased with how the business is executing in those areas.

Okay. Maybe just a quick question for Larry on Hep C.

Larry, have there been any decisions made about, if you look at the regimens in Pilot and Co-Pilot, about which of those regimens, if any, are going to be brought into Phase III?

No final decisions on Phase III at this point in time. I would say, one thing that we learned from Pilot/Co-Pilot, though, is that we used ABT-072 in Pilot.

That's our, again, the polymerase inhibitor, and we used 333 in Co-Pilot. As you can see, in the Phase IIb studies that we've described on clinicaltrials.gov, we are moving forward in Phase IIb with the ABT-333 polymerase.

But I think, more importantly, is the data that's coming from our broader Phase II program, Aviator and Navigator, that really combine and have various arms that have, again, various combinations of these 3 compounds with and without ribavirin, that will really be the guide to what we move forward with into Phase III. And again, right now, we're talking initiation of Phase III in 2013.

But as you can imagine, we're working very hard to have that occur as soon as we can. But that's our guidance today.

Okay. And then maybe just one quick -- I'm sorry, for John or Tom.

You talked about nutritional opportunities, obviously, a significant driver of what -- of DMP growth. You talked about 2 different opportunities: the first, which is a cost-driven opportunity; the second is mix.

I guess I'm just curious, can both of those opportunities move forward simultaneously? Or should we think of them as sort of a phase -- a phased effect?

No. I mean, all of the margin initiatives are being addressed concurrently as aggressively as the organization can do it.

So it's going to -- there's no reason to phase things. And there are numerous, numerous -- literally over 100 programs that the business is executing on as we speak.

Two questions. One on HUMIRA, the o U.S.

strength. Can you comment about -- I can't imagine it's entering new markets, so it must be indications.

So maybe discuss what's driving the international growth? Then my second question is on U.S.

stents. Can you give us a sense of what pricing has been doing in the market sequentially and what DES penetration was in the first quarter?

Yes. Let me take the last part first, Glenn.

So stent pricing actually has moderated nicely from what we've seen, as you know, last year, throughout the year. And I think the competitors saw this as well.

It was declining in the high-single digits. It's moderated to mid-single digits price decline.

And that is a function of a number of different things. One, on our end, is the launch of both nano and PRIME.

So getting into the short lengths and the longer lengths -- small vessels and longer lengths, excuse me. And that -- those are premium products, and I think that's helped stabilize as well, and some other competitive launches in addition.

So that's one thing. DES penetration has been around 80%.

And with PROMUS out of the mix as you know, too, that helps our overall pricing situation now that they're no longer part of that third-party revenue line in our overall numbers. So DES penetration is good.

PCI volume has been up nicely, particularly outside the U.S. and certain emerging markets, it's growing in the mid-teens.

So the dynamics there are good for the underlying business, despite the noise and as I mentioned on the call. And it's really about setting up the business for much stronger growth in 2013 as we get through this transition year, with PROMUS coming out of the numbers for us.

Can I ask one follow-up, just U.S. PCI volume is -- that's been kind of tracking flat to up a little, down a little.

Any indication what that was in the first quarter? And the 80% DES penetration, is that better than what we've seen in the second half of last year?

Yes, it is slightly better. We were seeing -- pushing upwards of 80%, 79%.

That's the first time that we've gotten to 80% in a while. And the U.S., you're right.

PCI volume there has been relatively flat and down just very slightly sequentially. But as I mentioned, up kind of in the mid-single digits worldwide.

And then certain international emerging markets been up quite strongly.

And then just the international HUMIRA growth?

Sure. Yes.

I think it's a combination of factors, Glenn. Certainly, HUMIRA has a leadership position and, as a leader, grows probably in excess of the marketplace most quarters.

That leadership extends across, as I said, now 7 indications. So it is somewhat driven by new indications.

It's also driven by some expansion in geographic presence. Japan continues to move forward nicely.

We've launched in China. But I think, in general, the overall driving factor is just market growth.

We continue to see, across the major markets, growth rates anywhere from 14% to 20%, just based again on the benefits that the product brings relative to the downstream cost that can be incurred for not treating the severity of these diseases. So market growth is probably your primary driver there in the international side, and we're growing a little bit faster than those markets.

And that 14% to 20%, should we assume it's closer to 14% in Europe and 20% outside of Europe? Or is it a little bit slower in Europe?

The Europes are in that range.

Just a follow-up on EPD. I think you guys reported in 2011, pricing was minus 1 to 2.

Is that still kind of the run rate you're seeing for that business?

Yes, that's probably about right. A little -- probably closer to 2.

Okay, fair enough. And I guess just following up on HUMIRA x U.S.

I know you don't want to get too specific on this, but is it reasonable to assume a double-digit ongoing constant currency-type growth for that product, again in international markets over the next few years?

Yes, it's always hard to project out that far, Rajeev. But again, here we are in 2012, and those markets continue to grow in the range that I just indicated.

That's pretty strong growth. Now certainly, our product gets bigger and bigger every year.

So dollars of growth can continue to be quite strong. The percentage, just based on the way the numbers work, starts to come down a little bit, but we foresee good growth there internationally.

Yes. I mean, you'll recall from the October investor meeting, Rick Gonzalez talked about $1 billion-plus in raw dollars of HUMIRA growth over the next few years.

So certainly, as a percentage, that would be double digits in '13 and probably '14. But that gives you an idea of what we think the continuing growth potential of the product is as we look out 2, 3 years.

Yes. No, that's very helpful.

It just seems like the product just continues to move ahead at a -- such a brisk pace. I appreciate the color.

Well, the performance has been good, and we think the durability is very strong as well over the long term.

Yes. And don't forget all the indications that we have.

And we just got another one, as you know, in Europe. So the utility of the product has been amazing, and it's a great, great, well-positioned product for the long-term.

Okay? All right.

And that concludes our conference call. A replay of the call will be available after 11 a.m.

Central Time today on our Investor Relations website at www.abbottinvestor.com; and after 11 a.m. Central Time via telephone at (203) 369-3838, confirmation code 70437043.

The audio replay will be available until 4 p.m. Central on Wednesday, May 2.

We appreciate you joining us, and please call us if you have any follow-up questions. Thank you for your time.